Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· July 29, 2026
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
View original at globenewswire.comMannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] co…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
According to the American Lung Association and GlobalData, there are an estimated 100,000 IPF patients in the U.S., a 20% rise in the last decade, and IPF affects an estimated 1-1.5 million people worldwide.
60% confidenceThe INFLO-1 results represent an important milestone for MannKind's nintedanib DPI program and further validate the potential of the Technosphere platform in pulmonary fibrosis; across Phase 1a and 1b studies, participants have received more than 700 inhalations of nintedanib DPI, including nearly 450 administered to people living with IPF, and cough was not a meaningful barrier to treatment.
60% confidence